Dionysios Nikolopoulos

Publications
Grants
CV
Public outreach and news

Articles

Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2026;:S0003-4967(26)00362-6
A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.
Nikolopoulos D; Pitsigavdaki S; Nöthling D-M; Katechis S; Nikoloudaki M; Bergmann C; Silvagni E; Repa A; Ramming A; Marangoni A; Govoni M; Sidiropoulos P; Fanouriakis A; Boumpas D; Schett G; Bortoluzzi A; Garantziotis P; Bertsias G
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2026;85(6):1140-1155
Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.
Papanikolaou S; Emmanouilidou E; Adamichou C; Kalogiannaki E; Nikolopoulos D; Fredi M; Carter LM; Tani C; Kapsala N; Repa A; Malissovas N; Garantziotis P; Avgoustidis N; Nikoleri D; Banos A; Vatsellas G; Sidiropoulos P; Konstantopoulos D; Boumpas D; Vital EM; Andreoli L; Mosca M; Inês L; Nikolaou C; Bertsias G
Article: ANNALS OF THE RHEUMATIC DISEASES. 2026;85(5):848-857
Untargeted breathomics identifies metabolic signatures of immune activity, intestinal integrity, and fatigue in systemic lupus erythematosus
Parodis I; Iacubino M; Rocco L; Nikolopoulos D; Palazzo L; Grimmett L; Kerr M; Bellocchi C; Vigone B; Santaniello A; Barturen G; Voskuyl AE; Alarcon-Riquelme ME; Beretta L
Article: CELLS. 2026;15(5):433
Glycomic Profiles of IgG, C3 and Alpha-1-Acid Glycoprotein (AGP) Before and One Year After Treatment for Active Lupus Nephritis
Nikolopoulos D; Cindric A; Charitidis K; Sherina N; Trbojevic BR; Pucic-Bakovic M; Simunovic J; Patenaude A-M; Pribic T; Tamirou F; Lauc G; Houssiau FA; Parodis I
Journal article: CELLS. 2026;15(5):433
Glycomic Profiles of IgG, C3 and Alpha-1-Acid Glycoprotein (AGP) Before and One Year After Treatment for Active Lupus Nephritis.
Nikolopoulos D; Cindrić A; Charitidis K; Sherina N; Radovani Trbojević B; Pučić-Baković M; Šimunović J; Patenaude A-M; Pribić T; Tamirou F; Lauc G; Houssiau FA; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2026;85(1):153-163
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus
Garantziotis P; Beretta L; Lindblom J; Moysidou G-S; Nikolopoulos D; Grieshaber-Bouyer R; Hagen M; Bergmann C; Wirsching A; Bozec A; Schneider M; Barturen G; Bertsias G; T Boumpas D; Alarcon-Riquelme ME; Mackensen A; Schett G; Parodis I
Article: JOURNAL OF TRANSLATIONAL AUTOIMMUNITY. 2025;11:100296
Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus
Lindblom J; Barturen G; Beretta L; Toro-Dominguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
Article: RMD OPEN. 2025;11(3):e006009
Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Garantziotis P; Nikolopoulos D; Katechis S; Temiz A; Nothling D-M; Adamichou C; Bergmann C; Sidiropoulos P; Schett G; Fanouriakis A; Boumpas DT; Bertsias G
Article: RHEUMATOLOGY. 2025;64(8):4650-4658
Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab
Depascale R; Da Mutten R; Lindblom J; Cetrez N; Palazzo L; Iaccarino L; Doria A; Nikolopoulos D; Gatto M; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(8):1342-1353
Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus
Nikolopoulos D; Sentis G; Kitsios I; Garantziotis P; Kapsala N; Pieta A; Flouda S; Manolakou T; Nikoloudaki M; Banos A; Chavatza K; Parodis I; Filia A; Bertsias G; Fanouriakis A; Boumpas DT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1164-1179
Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1
Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1180-1194
New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Sherina N; Nikolopoulos D
Article: RHEUMATOLOGY. 2025;64(7):4257-4266
Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2177
ABS0123 DISTINCT MOLECULAR RESPONSES TO CD19 CAR-T CELL THERAPY VERSUS STANDARD PHARMACOTHERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Garantziotis P; Beretta L; Lindblom J; Nikolopoulos D; Grieshaber-Bouyer R; Moysidou GS; Hagen M; Wirsching A; Taubmann J; Bergmann C; Bozec A; Barturen G; Fanouriakis A; Bertsias GK; Schneider M; Boumpas D; Alarcon-Riquelme M; Schett G; Parodis I
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:1267-1268
POS1203 GLYCOSYLATION CHANGES OF IgG, C3 AND ALPHA-1-ACID GLYCOPROTEIN (AGP) OVER ONE YEAR OF TREATMENT FOR INCIDENT LUPUS NEPHRITIS ARE ASSOCIATED WITH RENAL OUTCOME
Nikolopoulos D; Pučić-Baković M; Šimunović J; Patenaude AM; Vučković F; Pribić T; Tamirou F; Lauc G; Houssiau F; Parodis I
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2210
ABS0508 MACHINE LEARNING APPROACHES FOR PREDICTING EARLY ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Temiz A; Nikolopoulos D; Garantziotis P; Schett G; Fanouriakis A; Boumpas D; Bertsias GK
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:264-265
INTERFERON AND B LYMPHOCYTE DYSREGULATION PATTERNS DETERMINE DISTINCT LUPUS NEPHRITIS SUBGROUPS WITH DIFFERENTIAL ANTICIPATED RESPONSE TO TARGETED THERAPIES
Parodis I; Lindblom J; Toro-Dominguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcon-Riquelme M; Barturen G; Nikolopoulos D
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:260
MECHANISTIC BASIS FOR THE DISEASE MODIFYING EFFECTS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND MOLECULAR PREDICTORS OF RESPONSE BY BLOOD TRANSCRIPTOME ANALYSIS: EVIDENCE FOR A ROLE OF THE INNATE IMMUNITY (NEUTROPHILS, COMPLEMENT AND INTERFERON-Α) AND THE DNA DAMAGE RESPONSE
Moysidou GS; Garantziotis P; Grigoriou M; Nikolopoulos D; Sentis G; Nikoleri D; Filia A; Nikoloudaki M; Stergioti E; Malissovas N; Kapsala N; Fanouriakis A; Bertsias GK; Boumpas D
Article: RHEUMATOLOGY. 2025;64(6):3797-3805
Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting
Gomez A; Walhelm T; Loeff FC; Jonsen A; Nikolopoulos D; van den Broek B; Bengtsson AA; de Vries A; Rispens T; Sjowall C; Parodis I
Journal article: JOURNAL OF RHEUMATOLOGY. 2025;52:45
NOVEL IgG AND IgA AUTOANTIBODIES IN TWO INDEPENDENT COHORTS ASSOCIATE WITH GLOBAL AND ORGAN-SPECIFIC DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: IMPLICATIONS FOR ANTI-LIN28A AND ANTI-IRF5
Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Consortium PC; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme M; Nikolopoulos D; Parodis I
Show more

All other publications

Review: LUPUS. 2026;35(4):331-340
Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management
Demirtzoglou G; Damanaki A; Flouda S; Grigoriou M; Banos A; Nikolopoulos D; Boumpas DT
Review: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2026;22(1):19-29
Old and new autoantibodies in systemic lupus erythematosus
Parodis I; Nikolopoulos D; Brylid A; Hultgren O; Alarcon-Riquelme ME; Sjowall C
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025;27(1):37
Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus
Palazzo L; Tsoi A; Nikolopoulos D; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;84
GLYCOSYLATION CHANGES OF IgG, C3 AND ALPHA-1-ACID GLYCOPROTEIN (AGP) OVER ONE YEAR OF TREATMENT FOR INCIDENT LUPUS NEPHRITIS ARE ASSOCIATED WITH RENAL OUTCOME
Nikolopoulos D; Pucic-Bakovic M; Simunovic J; Patenaude AM; Vuckovic F; Pribic T; Tamirou F; Lauc G; Houssiau F; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;84:2177
DISTINCT MOLECULAR RESPONSES TO CD19 CAR-T CELL THERAPY VERSUS STANDARD PHARMACOTHERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS
Garantziotis P; Beretta L; Lindblom J; Nikolopoulos D; Grieshaber-Bouyer R; Moysidou GS; Hagen M; Wirsching A; Taubmann J; Bergmann C; Bozec A; Barturen G; Fanouriakis A; Bertsias GK; Schneider M; Boumpas D; Alarcon-Riquelme M; Schett G; Parodis I
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942-943
NOVEL IGG AND IGA AUTOANTIBODIES DIFFERENTIATING SYSTEMIC LUPUS ERYTHEMATOSUS FROM PRIMARY SJÖGREN'S SYNDROME AND SYSTEMIC SCLEROSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942.1-94942
IGG AND IGA AUTOANTIBODIES AGAINST NOVEL ANTIGEN SPECIFICITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIFFERENTIAL UNDERLYING MECHANISMS HERALDING PROMISE FOR EARLY DIAGNOSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3773-3774
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Manolakou T; Boddul S; Sentis G; Panagias MA; Samiotaki M; Nikolopoulos D; Slipicevic A; Sanjiv K; Henriksson M; Mortusewicz O; Chatzidionysiou A; Jakobsson P-J; Helleday T
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:4909-4910
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
Nikolopoulos D; Sentis G; Kitsos J; Garantziotis P; Kapsala N; Pieta A; Nikoloudaki M; Manolakou T; Flouda S; Parodis I; Filia A; Bertsias G; Fanouriakis A; Boumpas D
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3439-3440
IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
Parodis I; Nikolopoulos D; Lindblom J; Lagutkin D; Beretta L; Borghi MO; Peyper J; Barturen G; Jakobsson P-J; Alarcon-Riquelme M; Sherina N; Idborg H
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2024;76:3050-3053
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Parodis I; Lindblom J; Tsoi A; Nikolopoulos D; Beretta L
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1006-1007
BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:23-24
THE MOLECULAR LANDSCAPE OF ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS: DISTINCT TRANSCRIPTIONAL PROFILES IN VENOUS VERSUS ARTERIAL EVENTS, WITH POTENTIAL THERAPEUTIC IMPLICATIONS
Nikolopoulos D; Loukogiannaki C; Sentis G; Garantziotis P; Manolakou T; Kapsala N; Nikoloudaki M; Pieta A; Flouda S; Parodis I; Bertsias GK; Fanouriakis A; Filia A; Boumpas D
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2024;35(2):319
The Multiple Faces of Systemic Lupus Erythematosus: Pearls and Pitfalls for Diagnosis
Kapsala N; Nikolopoulos D; Fanouriakis A
Review: MEDITERRANEAN JOURNAL OF RHEUMATOLOGY. 2024;35(2):328
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus
Nikolopoulos D; Lourenco MH; Depascale R; Triantafyllias K; Parodis I
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2024;25(6):705-716
Advances in the pharmacological management of systemic lupus erythematosus
Tsoi A; Nikolopoulos D; Parodis I
Conference publication: 2024;:a24-a25
O23 Interferon upregulation and B and plasma cell gene dysregulation patterns reveal three distinct lupus nephritis subgroups with differential anticipated response to targeted therapies
Parodis I; Lindblom J; Toro-Domínguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcón-Riquelme ME; Barturen G; Nikolopoulos D
Conference publication: 2024;:a17-a18
O15 B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separate neuropsychiatric systemic lupus erythematosus patients into two distinct subgroups with differential anticipated response to targeted therapies
Lindblom J; Nikolopoulos D; Toro-Domínguez D; Carnero-Montoro E; Borghi MO; Castillo J; Iacobaeus E; Enman Y; Mohan C; Beretta L; Alarcón-Riquelme ME; Barturen G; Parodis I
Conference publication: 2024;:a59.1-a5a59
P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus
Lourenço MH; Cetrez N; Tsoi A; Lindblom J; Nikolopoulos D; Parodis I
Conference publication: 2024;:a28.2-a2a29
O28 Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Show more

Selected grants

Reumatikerförbundet – Juniora Forskare
1 October 2025 - 1 October 2028

Grants

Ulla och Gustaf af Ugglas stiftelse 2025
1 October 2025 - 1 October 2026
Gustaf V:s 80-årsfond (2025-2027)
31 May 2025 - 31 May 2027
Alex och Eva Wallströms stiftelse
31 March 2025 - 31 March 2027
Gustaf V:s 80-årsfond (2024-2025)
31 May 2024 - 31 May 2025
Ulla och Gustaf af Ugglas stiftelse 2023
1 October 2023 - 1 October 2024
Åke Wibergs Stiftelse
X-Hide ”starting grant”
Ulla och Roland Gustafssons Donationsfond 2024
Ulla och Roland Gustafssons Donationsfond 2025
Swedish Rheumatism Association 2025
Reumatikerförbundet - Stiftelsen Sigrid Anderssons fond 2024

Employments

Research Specialist, Department of Medicine, Karolinska Institutet, 2025-
Postdoctoral Researcher, Department of Medicine, Karolinska Institutet, 2023-2025

Degrees and Education

PhD, Immunology, Neuropsychiatric Lupus: Clinical and pathogenetic aspects, National and Kapodistrian University of Athens, 2022
MD, Medicine, National and Kapodistrian University of Athens, 2018

Articles

All other publications

Selected grants

Grants

Employments

Degrees and Education

News from KI

Events from KI